We regularly have new studies that we are recruiting for. If you don’t see something that you qualify for right now, please call Caitlin at 952-993-9605 to be contacted about future studies.
Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients (inRange)
Recruitment paused due to COVID-19
Principal Investigator: Richard Bergenstal, MD
Study Sponsor: Sanofi
Location: International Diabetes Center
Purpose of study: This study will compare how two different FDA approved long acting insulins work for people with type 1 diabetes. Participants will be provided with either insulin Tuojeo and Tresiba throughout the study to take in addition to their rapid acting insulin. Continuous glucose monitoring (CGM) will be used to measure glucose levels.
Inclusion Criteria: The study is accepting males and females ages 18-70 who:
• Have type 1 diabetes
• Take multiple daily insulin injections for their diabetes
• Have an A1C between 7.0-10.0%
• Meet other study specific requirements